UNSPSC 51434815: Pivopril

This classification denotes an ace inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3V6I5962EM. European Medicines Agency schedules Pivopril in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09952MIG. Pivopril generally arises in the molecular formula C16H27NO4S.

The term PIVOPRIL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 39, no. 5, 1985, list 25.) PIVOPRIL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule pivopril under HS 29309085 and SITC 51549. As of Q4 2014, PIVOPRIL remains the US FDA Preferred Term for this commodity. Pivopril bears US NLM identifiers UMLS ID C1882404 and NCI Concept Code C66443. SMILES: S(CC(C(=O)N(C1CCCC1)CC(=O)O)C)C(=O)C(C)(C)C.

UNSPSC 51434815 Pivopril is a Commodity code designating prescription pharmaceuticals for advanced life support and emergency medical use, as evidenced by recent state and local solicitations targeting sealed-bid procurements of critical-care injectable medications. State and local buyers acquire these drugs through direct-supply contracts with manufacturers and authorized wholesalers, with firm pricing, expiration-date guarantees, rapid delivery, and warranty requirements for use by fire rescue services, health agencies, and institutional care providers. Issuing bodies include city fire and rescue departments (Tampa Fire Rescue), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The mix reflects both individual-jurisdiction procurement for operational emergency-response needs and consolidated purchasing by multi-state cooperatives to manage volume across numerous member jurisdictions and hospitals.

Recent activity centers on three types of procurements. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications due April 8, 2026, requesting 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials with a one-year contract term and estimated value of $40,000.00, with a 5 percent SLBE bid discount not to exceed $10,000. The Texas Health and Human Services Commission released RFI HHS0017013 on March 27, 2026, with an April 3, 2026 response deadline, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program targeting negotiated net-pricing models outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration issued RFP S1070000015802 through MMCAP with a March 26, 2026 due date to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, effective July 1, 2026, with 75 percent evaluation weight on price competitiveness and mandatory compliance with cGMP and Drug Supply Chain Security Act standards. Geographic activity spans Florida (Tampa), Texas, and the upper Midwest (Minnesota, Oregon), with no current opportunities visible in other regions.